looking at a 4 bagger in 3 weeks, page-7

If the results are as good as the old ones were this will be massive.

Considering this will be one of the cheapest RA drugs to produce and the side effects of the other major players are things such as cancer then you would think a lot of patients will be looking to xtoll.

The only negative I think is that Novo Nordisk will pick up CBZ soon after results are released and we wont see the full potential.

Doesnt appear to be much interest amongst traders yet, will be a hard one for them to get on due lack of liquidity.
I have no intention of trading CBZ now as we get close to the phase 2 results.

Strap yourselves in.